Our purpose is to determine whether anthocyanins influence FKBP52 activation, leading to the reduction of hyper-phosphorylated Tau protein aggregations, and thereby relieving Alzheimer's disease. Here, FKBP4 is linked to early-onset autosomal dominant Alzheimer disease.